浅议药物警戒制度中药物有害反应的控制

doi:10.19803/j.1672-8629.2021.01.10

中国药物警戒 ›› 2021, Vol. 18 ›› Issue (1): 52-55.
DOI: 10.19803/j.1672-8629.2021.01.10

浅议药物警戒制度中药物有害反应的控制

宋英杰¹, 王海燕², 李雨嘉^1,*

¹山东大学齐鲁医学院药品监管科学研究院,山东济南 250014;
²山东现代学院医学院,山东济南 250104

收稿日期:2020-05-27 修回日期:2021-01-18 出版日期:2021-01-15 发布日期:2021-01-18
通讯作者: ^*李雨嘉,女,副研究员,医药高等教育管理研究。E-mail:liyuj@sdu.edu.cn
作者简介:宋英杰,女,硕士,主管药师,医药产业政策。

Prevention of Harmful Drug Reactions in Pharmacovigilance System

SONG Yingjie¹, WANG Haiyan², LI Yujia^1,*

¹Institute of Regulatory Science for Medical Products,Cheloo College of Medicine,Shandong University,Jinan Shandong 250014,China;
²School of Medicine,Shandong Modern University,Jinan Shandong 250104,China

Received:2020-05-27 Revised:2021-01-18 Online:2021-01-15 Published:2021-01-18

摘要/Abstract

摘要： 药物警戒制度贯穿于药品全生命周期,是对药品安全风险进行管理的最基本制度,它包含对药物有害反应的监测、识别、评估与控制,其中“控制”与其他三个过程一脉相承、相互交叉,是药物警戒制度相对药品不良反应监测制度最为先进性的体现,应当加强研究。本文通过梳理我国药物警戒制度的概念、分析我国对药物有害反应“控制”的实践以及国外药物有害反应“控制”的先进经验,建议从提高设计阶段的风险防控意识、把好注册审评审批关口、重视个案不良反应监测、制定药害救济制度、做好安全用药宣传、鼓励探索性研究等六个方面加强对药物有害反应的控制。

关键词: 药物警戒制度, 药物有害反应, 药品不良反应, 控制

Abstract: The pharmacovigilance system is the most basic system for drug safety risk management throughout the life cycle of drugs,involving the detection,identification,assessment and prevention of harmful drug reactions.Among the four tasks,prevention,which is the most advanced element of the pharmacovigilance system compared with the adverse drug reaction monitoring system,is overlapping with the other three,which is why the research on prevention should be strengthened.By interpreting the concept of pharmacovigilance systems in China ,analyzing China's practices and summarizing foreign experience on prevention of harmful drug reactions,this paper proposes that we can strengthen the prevention of harmful drug reactions by enhancing the awareness of risk prevention in the early stage of drug research and development,making registration review and approval rigorous,attaching importance to the monitoring of adverse reactions in individual cases,formulating relief systems for drug misadventures,promoting the safety of medicine use,and encouraging exploratory research.

Key words: pharmacovigilance system, harmful drug reactions, adverse drug reaction, prevention

中图分类号:

R951

宋英杰, 王海燕, 李雨嘉. 浅议药物警戒制度中药物有害反应的控制[J]. 中国药物警戒, 2021, 18(1): 52-55.

SONG Yingjie, WANG Haiyan, LI Yujia. Prevention of Harmful Drug Reactions in Pharmacovigilance System[J]. Chinese Journal of Pharmacovigilance, 2021, 18(1): 52-55.

参考文献

[1] Shi L,liu X,Zhang B.Study on recognition of drug toxicity in pharmacovigilance thought of the compendium of materia medica[J].Chinese Journal of Pharmacovigilance(中国药物警戒),2019,16(6):347-351.
[2] Guo PJ,Zhang B,Lin ZJ,et al.Analysis of pharmacovigilance thoughts in herbal masterpieces of Ming Dynasty[J].Chinese Journal of Experimental Traditional Medical Formulae(中国实验方剂学杂志),2020,26(5):186-191.
[3] Zhang XM,Xu MD,Chen WG.Research on national sentinel alliance for adverse drug reaction surveillance based on CHPS[J].Chinese Pharmaceutical Affairs(中国药事),2019,33(2):137-142.
[4] Cong LL,Bai YX,Li HY,et al.Comparison of pharmacovigilance information utilization in WHO,Europe,USA and China[J].Chinese Journal of New Drugs(中国新药杂志),2015,24(8):845-848,874.
[5] Yang Y.Implementation of pharmacovigilance system in drug administration law and application of ICH E2 Guideline[J].Chinese Journal of Pharmacovigilance(中国药物警戒),2020,17(2):65-71.
[6] Wang LL,Yang Y,Wang SL.Application of the US FDA sentinel system and enlightenment[J].Chinese Journal of Pharmacovigilance(中国药物警戒),2019,16(2):81-87.
[7] Stang P E,Ryan P B,Racoosin JA,et al.Advancing the science for active surveillance:Rationale and design for the observational medical outcomes partnership[J].Annals of Internal Medicine,2010,153(9):600-606.
[8] Zhang GJ,Chu XY,Tian YJ,et al.Implication of EU parmacovigilance system to China[J].Chinese Journal of Pharmacovigilance(中国药物警戒),2015,12(10):593-595,596.
[9] Arlett P,Strauss &Rasi G.Pharmacovigilance 2030[J].Clinical Pharmacology and Therapeutics,2020,107(1):89-91.
[10] Xu L,Zhao YJ,Li F,et al.Brief introduction and its implication on the drug risk management system in Japan[J].The Chinese Journal of Clinical Pharmacology(中国临床药理学杂志),2010,26(10):784-789.
[11] Zhong LM.MAHs’Principal responsibilities for safety risk during the whole-life cycle of drugs[J].Chinese Journal of Pharmacovigilance(中国药物警戒),2019,16(11):666-669,677.
[12] Yuan L,Shao ML.US FDA new drug expedited review strategies and its implications for China[J].Chinese Journal of New Drugs(中国新药杂志),2015,24(21):2401-2404,2409.
[13] National Medical Products Administration.Annual report for national adverse drug reaction monitoring (2019)[EB/OL].(2020-04-13)[2020-07-02].http://www.nmpa.gov.cn/WS04/CL2155/376451.html.
[14] Shu L.Analysis of common people's drug use behavior-report from "Survey of Safe Use of Drugs by common people"[J].Chinese Consumer Magazine(中国消费者杂志),2005(7):19-20.
[15] Stone NJ,Robinson G,LichtensteinAH,et al.2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines[J].Journal of the American College of Cardiology,2014,63(25):2889-2934.
[16] Cai RY.Analysis of whether Chinese ACS patients can tolerate high-intensity statin therapy according to clinical cases[J].Strait Pharmaceutical Journal(海峡药学),2018,30(9):240-243.

浅议药物警戒制度中药物有害反应的控制

Prevention of Harmful Drug Reactions in Pharmacovigilance System

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	贾晋生, 刘红亮, 王青, 侯永芳, 李馨龄. 基于知识图谱联合ERNIE-DPCNN模型的药品不良反应自动关联性评价方法研究[J]. 中国药物警戒, 2024, 21(2): 163-166.
[2]	李应芬, 韩雷. 319例注射用脑蛋白水解物药品不良反应报告分析[J]. 中国药物警戒, 2024, 21(2): 195-198.
[3]	徐伟佳, 彭崎, 黄海渝, 张磊姣, 肖华, 吴雪. 285例新型抗肿瘤药物不良反应分析[J]. 中国药物警戒, 2024, 21(2): 199-203.
[4]	郭清华, 彭笑笑, 朱萍, 刘西霖, 杨颖华, 陈志海. 氨氯地平过量致多器官功能障碍综合征1例分析[J]. 中国药物警戒, 2024, 21(2): 204-207.
[5]	方美琳, 郑慧敏, 王存泽, 王凌, 阮君山. 注射用奥沙利铂致全身肌肉疼痛1例分析[J]. 中国药物警戒, 2024, 21(2): 208-210.
[6]	陈玉艳, 张明霞, 张涛, 张晋. 斯鲁利单抗注射液致间质性肺炎不良反应1例分析[J]. 中国药物警戒, 2024, 21(2): 213-215.
[7]	曹桂萍, 邓琳琳, 朱干红, 陆颖, 马爽, 陈玲玲, 刘丽丽. 天麻首乌片致严重肝损伤1例分析[J]. 中国药物警戒, 2024, 21(2): 216-218.
[8]	高云娟, 赵旭, 白天凯, 柏兆方, 王伽伯, 宋海波, 肖小河. 基于不良反应监测大数据的药品安全风险发现与识别策略[J]. 中国药物警戒, 2024, 21(1): 1-5.
[9]	郭龙鑫, 高云娟, 吴承钊, 龙敏娟, 祝胜凯, 宋海波, 赵旭, 肖小河. 基于不良反应监测大数据的中药药源性肝损伤风险信号新发现及易感因素初探[J]. 中国药物警戒, 2024, 21(1): 15-19.
[10]	方志娥, 李承贤, 柏兆方, 赵旭, 王伽伯, 肖小河. 马兜铃酸致肝癌的客观性研究与思考[J]. 中国药物警戒, 2024, 21(1): 20-24.
[11]	蒋文硕, 杨莉. 694例癫痫医师药师联合门诊患者药品不良反应分析[J]. 中国药物警戒, 2024, 21(1): 102-106.
[12]	陈华炎, 江东波, 郭春连, 杨家琪, 黎雨欣, 蔡伟明. 326例奈玛特韦片/利托那韦片治疗新型冠状病毒感染安全性分析[J]. 中国药物警戒, 2024, 21(1): 107-110.
[13]	刘赛月, 吕小琴, 周耘. 疑似药品不良反应死亡病例调查及报告实施要点[J]. 中国药物警戒, 2023, 20(9): 971-974.
[14]	里筱竹, 王蔷, 逄瑜, 张轶菁. 个例药品不良反应报告管理浅析与思考[J]. 中国药物警戒, 2023, 20(9): 975-977.
[15]	逄瑜, 刘博, 吕少俐, 王涛, 邢颖, 秦星宇, 田月洁, 吴文宇. 基于国际药物警戒经验探讨收集患者报告的意义[J]. 中国药物警戒, 2023, 20(9): 978-981.